{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:11:07Z","timestamp":1776467467008,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T00:00:00Z","timestamp":1264550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11739-009-0342-4","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T12:38:20Z","timestamp":1264509500000},"page":"193-200","source":"Crossref","is-referenced-by-count":92,"title":["Infliximab-related hepatitis: discussion of a case and review of the literature"],"prefix":"10.1007","volume":"5","author":[{"given":"Stefano","family":"Mancini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Amorotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Ponz de Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Roncucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,27]]},"reference":[{"key":"342_CR1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00044011-200626110-00008","volume":"26","author":"E Ierardi","year":"2006","unstructured":"Ierardi E, Valle ND, Nocchiero MC, De Francesco V, Stoppino G, Panella C (2006) Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 26:673\u2013676","journal-title":"Clin Drug Investig"},{"key":"342_CR2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1161\/01.CIR.0000143630.14515.7C","volume":"110","author":"M Bourraindeloup","year":"2004","unstructured":"Bourraindeloup M, Adamy C, Candiani G, Cailleret M, Bourin MC, Badoual T, Su JB, Adubeiro S, Roudot-Thoraval F, Dubois-Rande JL, Hittinger L, Pecker F (2004) N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation 110:2003\u20132009","journal-title":"Circulation"},{"key":"342_CR3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Par\u00e9s A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW, International Autoimmune Hepatitis Group (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169\u2013176","journal-title":"Hepatology"},{"key":"342_CR4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum B\u00fcschenfelde KH, Zeniya M et al (1999) International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929\u2013938","journal-title":"J Hepatol"},{"key":"342_CR5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"DL Scott","year":"2006","unstructured":"Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704\u2013712","journal-title":"N Engl J Med"},{"key":"342_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"342_CR7","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","volume":"300","author":"TJ Giezen","year":"2008","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887\u20131896","journal-title":"JAMA"},{"key":"342_CR8","unstructured":"Approval history and label\u2014Infliximab (Remicade\u00ae), Centocor Inc. Accessed online, 7 April 2009 at http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label ApprovalHistory#apphist"},{"key":"342_CR9","unstructured":"US Food and Drugs Administration (2004) Warning on severe hepatotoxicity with Remicade. US Food and Drugs Administration MedWatch, Rockville. Accessed online, 7 April 2009 at http:\/\/www.fda.gov\/medWatch\/safety\/2004\/remicade_DHCP_dec04.pdf"},{"key":"342_CR10","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"EA Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors (activated macrophage). Proc Nat Acad Sci USA 72:3666\u20133670","journal-title":"Proc Nat Acad Sci USA"},{"key":"342_CR11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745\u2013756","journal-title":"Nat Rev Immunol"},{"key":"342_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02934736","volume":"1","author":"S Romagnani","year":"2006","unstructured":"Romagnani S (2006) Immunological tolerance and autoimmunity. Intern Emerg Med 1:187\u2013196","journal-title":"Intern Emerg Med"},{"key":"342_CR13","unstructured":"Remicade\u00ae\u2014Infliximab, Centocor, Inc. Product Label. Accessed online, 23 April 2009 at http:\/\/www.fda.gov\/cder\/foi\/label\/2008\/103772s5232lbl.pdf"},{"key":"342_CR14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L Rycke De","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48:1015\u20131023","journal-title":"Arthritis Rheum"},{"key":"342_CR15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"342_CR16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn\u2019s disease: theACCENT I randomised trial. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"342_CR17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374","journal-title":"Lancet"},{"key":"342_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","volume":"76","author":"VV Menghini","year":"2001","unstructured":"Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84\u201386","journal-title":"Mayo Clin Proc"},{"key":"342_CR19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/1529-0131(200108)44:8<1966::AID-ART339>3.0.CO;2-3","volume":"44","author":"G Saleem","year":"2001","unstructured":"Saleem G, Li SC, MacPherson BR, Cooper SM (2001) Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 44:1966\u20131968","journal-title":"Arthritis Rheum"},{"key":"342_CR20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/ard.2003.006775","volume":"63","author":"M Feletar","year":"2004","unstructured":"Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12-month observational study of 16 patients. Ann Rheum Dis 63:156\u2013161","journal-title":"Ann Rheum Dis"},{"key":"342_CR21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519\u20131520","journal-title":"Ann Rheum Dis"},{"key":"342_CR22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Ca\u00f1as C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578\u2013581","journal-title":"Clin Rheumatol"},{"key":"342_CR23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-006-0253-y","volume":"26","author":"AM Garc\u00eda Aparicio","year":"2007","unstructured":"Garc\u00eda Aparicio AM, Rey JR, Sanz AH, Alvarez JS (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26:811\u2013813","journal-title":"Clin Rheumatol"},{"key":"342_CR24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1157\/13087475","volume":"29","author":"S Soto-Fernandez","year":"2006","unstructured":"Soto-Fernandez S, Gonzalez-Carro P, De Pedro-Esteban A et al (2006) Infliximab-induced hepatitis in a patient with Crohn\u2019s disease. Gastroenterol Hepatol 29:320\u2013322","journal-title":"Gastroenterol Hepatol"},{"key":"342_CR25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2230.2006.02086.x","volume":"31","author":"S Wahie","year":"2006","unstructured":"Wahie S, Alexandroff A, Reynolds NJ (2006) Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 31:460\u2013461","journal-title":"Clin Exp Dermatol"},{"key":"342_CR26","first-page":"524","volume":"187","author":"G Ozorio","year":"2007","unstructured":"Ozorio G, McGarity B, Back H, Jordan AS, Lau H, Marshall C (2007) Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. MJA 187:524\u2013526","journal-title":"MJA"},{"key":"342_CR27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ibd.20293","volume":"14","author":"M Marques","year":"2008","unstructured":"Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, Costa Santos C (2008) Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 14:723\u2013725","journal-title":"Inflamm Bowel Dis"},{"key":"342_CR28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-008-1000-3","volume":"27","author":"H Becker","year":"2008","unstructured":"Becker H, Willeke P, Domschke W, Gaubitz M (2008) Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 27:1597\u20131598","journal-title":"Clin Rheumatol"},{"key":"342_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jbspin.2007.12.009","volume":"75","author":"G Thi\u00e9fin","year":"2008","unstructured":"Thi\u00e9fin G, Morelet A, Heurgu\u00e9 A, Diebold MD, Eschard JP (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737\u2013739","journal-title":"Joint Bone Spine"},{"key":"342_CR30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2230.2008.03088.x","volume":"34","author":"DA Fairhurst","year":"2009","unstructured":"Fairhurst DA, Sheehan-Dare R (2009) Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 34:421\u2013422","journal-title":"Clin Exp Dermatol"},{"key":"342_CR31","doi-asserted-by":"crossref","unstructured":"Carlsen KM, Riis L, Madsen OR (2009) Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol","DOI":"10.1007\/s10067-009-1179-y"},{"key":"342_CR32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2340\/00015555-0619","volume":"89","author":"N Kluger","year":"2009","unstructured":"Kluger N, Girard C, Guillot B, Bessis D (2009) Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol 89:332\u2013334","journal-title":"Acta Derm Venereol"},{"key":"342_CR33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1478-3231.2006.01339.x","volume":"26","author":"H Tilg","year":"2006","unstructured":"Tilg H, Kaser A, Moschen AR (2006) How to modulate inflammatory cytokines in liver diseases. Liver Int 26:1029\u20131039","journal-title":"Liver Int"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-009-0342-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0342-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T17:21:33Z","timestamp":1559409693000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-009-0342-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,27]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s11739-009-0342-4","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,27]]}}}